Results 211 to 220 of about 122,409 (259)

Engineering antibodies with cancer‐associated binding sites

open access: yesBMEMat, EarlyView.
This review describes antibodies that perform direct/indirect roles in cancer treatment by binding to effective targets and discusses how antibodies kill tumors and modulate tumor microenvironment through these targets. The classification of expression systems for antibody production is summarized to guide appropriate selection based on different ...
Yinqi Tian   +4 more
wiley   +1 more source

Extracorporeal Photopheresis Enhances the Frequency and Function of Highly Suppressive FoxP3 + Treg Subsets in Heart Transplanted Individuals. [PDF]

open access: yesTransplantation
Mottola M   +16 more
europepmc   +1 more source

Designing next‐generation immune cell therapies with nanomaterials

open access: yesBMEMat, EarlyView.
Nanomaterials are transforming immune cellular therapies (ICT) by addressing challenges like tumor accessibility and lengthy manufacturing. This perspective highlights innovations such as magnetic nanoparticles for target identification, lipid nanoparticles for T cell stimulation, and nanoparticle‐mediated gene cytokine delivery. These advances promise
Kangfu Chen, Wenhan Wang, Zongjie Wang
wiley   +1 more source

5‐Aza combined with VPA reprograms human T lineage acute leukemia Jurkat cells into B‐cell‐like cells by epigenetic activation of PAX5

open access: yesBiotechnology Progress, EarlyView.
Abstract Epigenetic regulation plays an important role in cell fate reprogramming. Here, we found that inhibitors of epigenetic modifiers, including VPA, TSA, and 5‐Aza‐2'‐deoxycytidine, can induce phenotypic transformation from Jurkat cells into B‐cell‐like cells. When Jurkat cells were treated with 5‐Aza combined with VPA, B cell and stem cell marker
Wenjin Xi   +11 more
wiley   +1 more source

CD73 promotes the immunoregulatory functions of hepatic Tregs through enzymatic and nonenzymatic pathways in MASLD development. [PDF]

open access: yesMol Metab
Jin H   +12 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy